Research Report 2010 2011 - Helmholtz-Zentrum für ...

40 RESEARCH REVIEWS | Novel Nanoparticle-based Technology Platform for the Delivery of Vaccine Antigens
In 2005 he was appointed as Head of the new HZI Department
of Vaccinology. He has been working in the field of
Vaccinology since 1989. His work has been instrumental for
the development of new adjuvants and the establishment of
Salmonella spp. as a delivery system for DNA vaccines and
therapeutic molecules.
Steffi Hansen studied pharmacy at Ernst-Moritz-Arndt
Universität, Greifswald and graduated 2004 with a diploma
in pharmacy. 2004 she also received her approbation as a
pharmacist. From 2005 to 2009 she joined the department of
Prof. Claus-Michael Lehr at Saarland University to prepare
her doctoral thesis entitled „Development of a physiology
based diffusion model to predict dermal absorption using
experimental input parameters“. Subsequently Steffi Hansen
started a postdoc at University of Cincinnati, USA sponsored
by the German Academic Exchange Service (DAAD). She
came back to Saarland to the newly founded Helmholtz-Institute
for Pharmaceutical Research in 2010 where she works as
a project leader on new strategies for transdermal vaccinations
on immune homeostasis and aging.
Carlos A. Guzmán born in 1959, is Head of the Department
of Vaccinology and Applied Microbiology at the Helmholtz
Centre for Infection Research (Braunschweig, Germany) and
APL-Professor at the Medical School of Hannover. He is also
external Lecturer of the Doctorate in Biotechnology from the
University of Catania (Italy). He graduated in Medicine at
the National University of Rosario (1981) and obtained his
Board Certification in Medical Bacteriology (1986) in Argentina.
In 1987, he moved to the Institute of Microbiology from
the University of Genoa (Italy), as Research Fellow from the
Italian Foreign Office Ministry. In Italy he also graduated as
Doctor of Medicine and Surgery and obtained his Doctorate
of Research in Microbiological Sciences. In 1994 he moved
to Germany, where he became Head of the Vaccine Research
Group at the German Research Centre for Biotechnology.
Ulrich Schäfer studied Pharmacy at Kiel University
from 1971 to 1974 and qualified as pharmacist in 1974. He
obtained his Ph.D. at the Saarland University in 1980 for his
thesis work on dissolution processes of poorly soluble
substances. In 1994, he was nominated as a so-called
‚Fachapotheker‘ for Pharmaceutical Technology. In 1995, he
was permitted to further educate Pharmaceutical Technology
as a professional training. Dr. Schäfer is member of the
CRS, the APV, and the DPhG. His research interests are the
biopharmaceutical investigations of semisolid dosage forms
for dermatological applications, the development of ex vivo
models for the determination of penetration of drugs and
preservatives into human skin, the optimization of (trans)
dermal dosage forms, and the solubility improvement of
poorly soluble drugs. In December 2010, he was appointed
APL Professor from the President of Saarland University as
appreciation for his commitment and achievements in the
Pharmaceutical Sciences.